REFERENCES
- LaVallie ER, Dorner AJ, Burczynski ME. Use of ex vivo systems for biomarker discovery. Curr Opin Pharmacol 2008;8: 647–653.
- Phillips RL, Sachs AB. Skin biopsies for the measurement of clinical pharmacodynamic biomarkers. Curr Opin Biotechnol 2005;16:687–690.
- Groeber F, Holeiter M, Hampel M, Hinderer S, Schenke-Layland K. Skin tissue engineering–in vivo and in vitro applications. Adv Drug Deliv Rev 2011;63:352–366.
- Gibbs S. In vitro irritation models and immune reactions. Skin Pharmacol Physiol 2009;22:103–113.
- Ponec M. Skin constructs for replacement of skin tissues for in vitro testing. Adv Drug Deliv Rev 2002;54(Suppl 1):S19–S30.
- Semlin L, Schafer-Korting M, Borelli C, Korting HC. In vitro models for human skin disease. Drug Discov Today 2011;16:132–139.
- Pendergast A. Nuclear tyrosine kinases: from Abl to Wee1. Curr Opin Cell Biol 1996;8:174–181.
- Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, Kimura T, Kaneko N, Ohtani J, Yamanaka K, Itadani H, Takahashi-Suzuki I, Fukasawa K, Oki H, Nambu T, Jiang J, Sakai T, Arakawa H, Sakamoto T, Sagara T, Yoshizumi T, Mizuarai S, Kotani H. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther 2009;8:2992–3000.
- Mizuarai S, Yamanaka K, Itadani H, Arai T, Nishibata T, Hirai H, Kotani H. Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor. Mol Cancer 2009;8:34.
- Wirtz MK, Glanville RW, Steinmann B, Rao VH, Hollister DW. Ehlers-Danlos syndrome type VIIB. Deletion of 18 amino acids comprising the N-telopeptide region of a pro-alpha 2 (I) chain. J Biol Chem 1987;262:16376–16385.
- Zambruno G, Marchisio P, Marconi A, Vaschieri C, Melchiori A, Giannetti A, De Luca M. Transforming growth factor-b1 modulates b1 and b5 integrin receptors and induces de novo expression of the avb6 heterodimer in normal human keratinocytes: implications for wound healing. J Cell Biol 1995;129:853–865.
- Asselineau D, Bernard BA, Bailly C, Darmon M. Epidermal morphogenesis and induction of 67 kD keratin polypeptide by culture at the liquid-air interface. Exp Cell Res 1985;159:536–539.
- Asselineau D, Bernard BA, Bailly C, Darmon M. Retinoic acid improves epidermal morphogenesis. Dev Biol 1989;133: 322–335.
- Ponec M, Weerhaim A, Kempenaar J, Mulder A, Gooris GS, Bouwstra J, Mommaas AM. The formation of competent barrier lipids in reconstructed human epidermis requires the presence of vitamin C. J Invest Dermatol 1997;109:348–355.
- Hu X, Moscinski LC. Cdc2: a monopotent or pluripotent CDK? Cell Prolif 2011;44:205–211.
- Lindqvist A, Rodriguez-Bravo V, Medema RH. The decision to enter mitosis: feedback and redundancy in the mitotic entry network. J Cell Biol 2009;185:193–202.
- Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson RI, Baselga J. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002;20:110–124.
- Malik SN, Siu LL, Rowinsky EK, deGraffenried L, Hammond LA, Rizzo J, Bacus S, Brattain MG, Kreisberg JI, Hidalgo M. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res 2003;9:2478–2486.